Urogenital medical device formulation based on suitable biochemical compositions for the stabilization of the acidity and the redox state of the vaginal fluid

A method for treating or preventing urogenital infections caused by pathogenic microorganisms in a female subject, comprising the following steps:

• (a) providing a composition having a pH from 4.3 to 4.6 comprising the following ingredients per single dosage:
• i) calcium-lactate pentahydrate:
• 30-90 mg,
• ii) dibasic magnesium citrate:
• 15-45 mg,
• iii) prebiotic fiber:
• 15-150 mg,
• iv) glutamic acid:
• 20-60 mg,
• v) cystine or thiosulfate:
• 10-50 mg, and
• vi) excipients to 400-1100 mg;
• and
• (b) administering the composition intravaginally to the subject in need of treatment for stabilizing the acidity of the vaginal fluid of the subject at the physiological value around pH 4.5 or lower.

The method according to claim 1, wherein the composition comprises:

• i) calcium-lactate pentahydrate:
• 60 mg;
• ii) dibasic magnesium citrate:
• 30 mg;
• iii) prebiotic fiber:
• 100 mg;
• iv) glutamic acid:
• 40 mg;
• v) cystine or thiosulfate:
• 30 mg;
• and
• vi) excipients to 400-1100 mg.

A prebiotic vaginal lubricant comprising:

• i) lactic acid:
• 50 mg;
• ii) citric acid:
• 30 mg;
• iii) glycerol:
• 80 mg;
• iv) carbomer:
• 5 mg;
• v) short-chain fructo-oligosaccharides:
• 50 mg;
• vi) thiosulfate:
• 10 mg;
• vii) glutamic acid:
• 10 mg;
• and
• viii) NaOH 0.1 M or HCl 0.1 M to pH 4.5 of the lubricant.

A method of treating or preventing bacterial vaginosis in a subject, comprising the following steps:

• (a) providing a vaginal capsule comprising:
• i) lyophilisates of vaginal strains L. gasseri 120.1 deposited by Medinova AG at Collection Nationale de Cultures de Microorganismes (CNCM) on Jun. 4, 2004 with accession number CNCM I-3218 and L. gasseri 124.3 deposited by Medinova AG at Collection Nationale de Cultures de Microorganismes (CNCM) on Jun. 4, 2004 with accession number CNCM I-3220 at concentrations of 1011 c.f.u./g:
• 100 mg each;
• ii) calcium-lactate pentahydrate:
• 60 mg;
• iii) dibasic magnesium citrate:
• 30 mg;
• iv) alanine:
• 40 mg;
• v) arabinogalactan:
• 100 mg;
• vi) dimethyl sulfone (MSM):
• 30 mg;
• vii) excipients:
• 140 mg;
• and
• (b) administering the vaginal capsule to the subject in need of treatment.